Understanding JAK1 Inhibitors and Allergic Skin Disease

Atinvicitinib is a Janus kinase 1 inhibitor developed for use in dogs with allergic skin disease. This article explains how JAK1 inhibitors work, how allergic dermatitis affects dogs, and why treatment decisions should always be made by a veterinary surgeon.

Allergic skin disease is a common cause of itching in dogs. Advances in veterinary medicine have led to the development of targeted therapies that act on specific inflammatory pathways involved in allergic conditions.

One such approach involves the use of Janus kinase inhibitors, commonly known as JAK inhibitors. These medicines interfere with signalling pathways that contribute to inflammation and itch.

Atinvicitinib is a newer JAK inhibitor developed for use in dogs with allergic skin disease. It has received regulatory approval in Europe and may be considered by veterinary surgeons where clinically appropriate.

What is atinvicitinib?

Atinvicitinib is a second generation Janus kinase inhibitor. It works by targeting intracellular signalling pathways used by inflammatory cytokines.

It has been developed to be selective for the JAK1 enzyme, which plays a key role in allergic inflammation and itch signalling.

• Drug class: Janus kinase inhibitor
• Target: JAK1 signalling pathways
• Administration: Oral tablets, as prescribed by a veterinary surgeon
• Dosing: Determined by the prescribing veterinary surgeon

Medicines in this class are classified as prescription only veterinary medicines and can only be supplied against a valid veterinary prescription.

What is atinvicitinib used for in dogs?

Veterinary surgeons may consider JAK inhibitors, including atinvicitinib, as part of the management of allergic skin disease in dogs.

These conditions may include:

• Pruritus associated with allergic dermatitis
• Clinical signs of canine atopic dermatitis

Allergic dermatitis occurs when the immune system reacts to environmental allergens such as pollen, house dust mites or mould spores.

Common clinical signs may include:

• Persistent scratching
• Licking or chewing paws
• Red or inflamed skin
• Recurrent ear problems
• Hair loss
• Secondary skin infections

How do JAK inhibitors work?

Allergic itching is driven by signalling molecules known as cytokines. These activate pathways inside immune cells that contribute to inflammation and itch sensation.

Many of these pathways rely on Janus kinase enzymes, particularly JAK1.

JAK inhibitors act by blocking these pathways, which may help reduce inflammation and interrupt the itch cycle in affected dogs.

Different JAK inhibitors vary in their selectivity and pharmacological profile, which may influence how they are incorporated into individual treatment plans.

Why is itch control important?

Chronic itching can significantly affect a dog's quality of life. Dogs with allergic skin disease may scratch, lick or chew repeatedly, which can lead to skin trauma, inflammation and secondary infection.

Managing the itch cycle is often an important part of treating allergic skin disease. However, itch control is only one part of management, and veterinary surgeons may also investigate underlying triggers, secondary infections and long term skin health.

Clinical evidence

JAK inhibitors have been evaluated in clinical studies involving dogs with allergic dermatitis and atopic dermatitis.

In controlled studies, treatment with JAK inhibitors has been associated with reductions in pruritus and skin lesions compared with placebo.

Response to treatment can vary between individual dogs, and ongoing monitoring by a veterinary surgeon is required.

Further information can be found in regulatory documentation and published clinical data.

Other treatment approaches for allergic skin disease

Allergic skin disease is often managed using a combination of approaches. The most appropriate plan depends on the individual dog, the severity of clinical signs and the veterinary surgeon's assessment.

Treatment and management options may include:

• Targeted anti itch therapies
• Monoclonal antibody therapies targeting itch pathways
• Immunomodulatory medicines
• Management of secondary bacterial or yeast infections
• Parasite control
• Dietary trials where food allergy is suspected
• Allergen avoidance where possible
• Skin barrier support and topical therapy

The most appropriate approach depends on the individual patient, underlying disease and clinical judgement of the veterinary surgeon.

How is atinvicitinib prescribed in the UK?

Atinvicitinib is classified as a prescription only veterinary medicine. Medicines in this category can only be prescribed by a veterinary surgeon following clinical assessment.

Treatment decisions are based on the individual patient's needs, clinical history, concurrent conditions and response to previous therapies.

Owners should discuss suitable treatment options directly with their veterinary surgeon.

Frequently Asked Questions

Is atinvicitinib suitable for every itchy dog?

No. It may not be suitable for every patient. The prescribing veterinary surgeon will consider the dog's diagnosis, age, health status, concurrent medications and clinical history before deciding whether treatment is appropriate.

Does atinvicitinib treat the cause of allergic skin disease?

JAK inhibitors help target inflammatory and itch signalling pathways. They do not necessarily remove the underlying allergic trigger, so broader management may still be needed.

Can owners start treatment without seeing a vet?

No. Prescription only veterinary medicines require veterinary assessment and a valid veterinary prescription.

What should I do if my dog is itchy?

If your dog has persistent itching, inflamed skin, recurrent ear problems or repeated skin infections, arrange an assessment with your veterinary surgeon.